Abstract: PO1807
Long-Term Outcomes After Renal Revascularization for Atherosclerotic Renovascular Disease in the ASTRAL Trial
Session Information
- Hypertension and CVD: Clinical, Outcomes, and Trials
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1402 Hypertension and CVD: Clinical, Outcomes, and Trials
Authors
- Kalra, Philip A., Salford Royal Hospital, Salford, Salford, United Kingdom
- Green, Darren, Salford Royal Hospital, Salford, Salford, United Kingdom
- Ives, Natalie, University of Birmingham, Birmingham, Birmingham, United Kingdom
Group or Team Name
- The ASTRAL trial investigators
Background
The Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial recruited 806 patients with atherosclerotic renal artery stenosis (RAS) between 2000-2007, randomised 1:1 to medical therapy with or without renal artery stenting. The initial results were presented in 2009 at median follow-up 34.6 months when no benefit of revascularization to renal functional outcome or cardiovascular events (CVE) were evident. Surviving patients remained under follow up until 2014.
Methods
All available data were analysed to assess whether there was a later impact of revascularization on renal function, CVE and survival, including a composite outcome of renal and CV outcomes and death (as used in the CORAL trial). Pre-specified sub-group analyses of different categories of renal function, renal length, prior rapid deterioration in kidney function, and severity of RAS. Further post-hoc analysis of patients with severe RAS (defined as bilateral 70% or > 70% RAS in a solitary kidney = global renal ischemia), those with/without proteinuria and a per protocol analysis were performed.
Results
The mean age of the entry population was 70.5 years, mean eGFR 40 ml/min/1.73m2, with mean RAS 76% and blood pressure 150/76 mmHg; 83% of the revascularization group underwent attempted stenting. Median follow-up was 56.4 months with 108 patients lost to follow up or withdrawn; 50% of the evaluable population had died, 14% had received RRT and 40% had suffered a 1st CVE. No benefit of revascularization was observed for any outcome in the intention to treat and per protocol analyses, either in the whole population or the pre-specified sub-groups. In the severe RAS sub-group (163 patients) revascularization was associated with a hazard ratio (HR) of 0.74 (0.54-1.01; p=0.062) for the composite renal and CV outcome and an HR of 0.70 (0.49-1.0) for death (p=0.051).
Conclusion
The long-term follow-up of the ASTRAL trial population showed no overall benefit of renal revascularization to renal and CV outcomes. It has been highlighted that a proportion of the population had lower risk mild-moderate RAS. The long-term outcomes in patients with severe RAS (global renal ischemia) point to a potential benefit of stenting that may be worthy of further study in a more selected population.
Funding
- Government Support – Non-U.S.